Gemcitabine in NK/T Cell Lymphoma

Completed

• Conditions: NK/T Cell Lymphoma

• Registration Number: NCT01660568
• Lead Sponsor: Samsung Medical Center

Brief Summary

We retrospectively review patients with refractory or relapsed ENKL who received a gemcitabine-containing regimen

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2012-08
• Study Start: 2012-08
• Study First Submitted: 2012-08-06
• Study First Submitted QC: 2012-08-07
• Study First Posted: 2012-08-08
• Primary Completion: 2013-01
• Study Completion: 2013-01
• Last Update Submitted: 2013-02-11
• Last Update Posted: 2013-02-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• NK/T cell lymphoma
• relapse or refractory disease
• gemcitabine containing treatment

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall response rate	2012-May

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of